Dr. Le on Treatment Approaches for Oligometastatic Colorectal Cancer

Article

In Partnership With:

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

The treatment of patients with oligometastatic CRC is evolving, says Le. Historically, clinical trials for patients with oligometastatic disease were limited to those with less than 3 or 4 sites of localized metastases. However, in clinical practice, patients could have more than 4 metastatic sites of disease and still be considered oligometastatic.

In the absence of robust clinical trial data, it’s important to have a multidisciplinary team help determine which patients with oligometastatic disease require more aggressive therapy versus those who don’t, concludes Le.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD